In Q3 2015, we surveyed 51 CEOs of US-based biopharmaceutical companies.  Download a white paper summary for the Q3 2015 survey. The paper includes conclusions that are relevant to C-suite executives and cross-functional leaders in industry as well investors and service providers supporting the industry.

In summary:

  • 100% were very or somewhat confident in their companies and overall industry
  • Single largest risk to their companies is capital stability (35%) and clinical results (33%)

Across the Six Key Indicators

1. Capital Markets

  • 86% confident in fund-raising prospects
  • 86% confident to raise capital within 18 months
  • 14% not looking to raise capital

2.  Deal Landscape

  • 74% confident in out-licensing within 18 months
  • 82% confident in M&A and partnering market

3.  Clinical Development

  • 100% confident in their clinical differentiation
  • 68% outsourced 50-100% of clinical studies

4.  Regulatory Affairs

  • 84% confident in regulatory environment
  • 53% to 69% very confident in filing NDA/BLA in 4-5 years

5.  Commercialization

  • Less than 50% confident in commercial capabilities
  • Only 28% plan to commercialize independently

6.  Business Model and Workforce

  • 94% confident in current internal resources
  • 78% will increase staff by more than 10%

To view past results, click here

The results of this Index and the implications are much more impactful and applicable to any company’s business situation when they are delivered in person. Request that a Kineticos team member present the full Index and survey results to your organization

The Biopharma CEO Confidence Index is a partnership between KineticosIpsos Healthcare, and. Demy-Colton Life Science Advisors.

purple-with-taglineDemy Colton Logo